|
Per clinical trial cp-1060: on (b)(6) 2018, patient underwent bilateral breast reduction; medial pedicle using a wise pattern superomedial pedicle incision.2 pieces of galaflex were used.On (b)(6) 2018, bilateral breast seroma was reported.Sae.On (b)(6) 2018, patient had aspiration of seromas.Serosanguinous drainage aspirated from both breasts over several dates.Resolved without sequelae on 6/5/18.Review by medical affairs identifies the reported seroma is likely related to the device and serious.
|
|
Based on the information provided, no conclusions can be made.As reported, patient experienced post-op complication of seroma and underwent drainage.Medical affairs has assessed the patient¿s postoperative course as being serious and likely related to the study device.Review of the device history records confirmed the device was manufactured to specification.Seroma is a known inherent risk of surgery/use of the device and is included as a possible complication in the adverse reaction section of the instructions-for-use (ifu).Note: this mdr report is related to a retrospective study conducted to proactively gather real-world evidence on the use and safety of the p4hb product family, including galaflex scaffold, galaflex 3d, and galaflex 3dr. all safety events from the study are adjudicated by the bd medical monitor for an independent assessment of severity and relatedness. in an abundance of caution, events for which relatedness cannot be ruled out are processed for mdr reporting.Device not returned - remains implanted.
|